Evaluating the Evidence for Long-Term Benefit from Specialty Centers Versus Real World for MDS Patients Treated with HMA

Conclusions: In matched analysis, MDS pts treated with HMAs at CRC centers have significantly better survival in the first year following diagnosis compared to SEER. The lowered risk of first year mortality following MDS diagnosis in pts treated with HMA at CRC compared to SEER is likely the result of earlier detection, earlier time to treatment, selection bias for healthier pts, and availability of clinical trials. Conditional survival probabilities beyond 12 months are comparable between real-world and specialty centers, an effect that most likely reflects the natural history of disease progression, loss of response to HMAs or lack of effective therapies beyond HMAs. These findings emphasize the need to factor in real world data in designing rigorous clinical trials to include mortality reduction beyond 12 months among several study end points to more comprehensively assess treatment effectiveness.DisclosuresMukherjee: LEK Consulting: Consultancy, Honoraria; Takeda: Membership on an entity's Board of Directors or advisory committees; BioPharm Communications: Consultancy; Projects in Knowledge: Honoraria; Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Takeda Pharmaceuticals: Membership on an entity's Board of Directors or advisory committees; Bristol Myers Squib: Honoraria, Speakers Bureau; Pfizer: Honoraria; Aplastic Anemia & MDS International Foundation in Joint Partnership with Cleveland Clinic Taussig Can...
Source: Blood - Category: Hematology Authors: Tags: 637. Myelodysplastic Syndromes-Clinical Studies: Poster II Source Type: research